About US
Contact us
-
Aegerion's Juxtapid capsules approved for treatment of HoFH patients in MexicoThe Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has approved Aegerion Pharmaceuticals' Juxtapid (lomitapide) capsules for the treatment of homozygous familial hyperc2014/1/22
-
2D Barcode Scanner for Frozen SamplesMicronic, specialists in traceable sample storage solutions, has announced a further addition to its popular ‘blue-white’ Tracxer Code Reader line. The Tracxer Code Reader RD235 CRYO offers a high-2014/1/22
-
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic TestsHorizon Discovery Ltd, a leading provider of research tools to support translational genomics and the development of personalised medicines, and Transgenomic, Inc., a global biotechnology company adva2014/1/21
-
Mundipharma acquires rights to patents for heroin substitution from PhoenuxUK-based Mundipharma International has acquired exclusive global rights to a family of patents for heroin substitution, including a morphine/naloxone combination from Phoenux. In Europe about 1.4 mil2014/1/21
-
Gastrointe​stinal Therapeuti​cs Industry: Promising Drugs in Late-Stage Developmen​t Could Stabilise Declining Global MarketThe gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Ital2014/1/20
-
Zealand's partner Sanofi to start first Phase III study of LixiLan in Q1 2014Denmark-based Zealand Pharma has announced that the first LixiLan Phase III trial protocol has been approved, triggering a $15m payment from Sanofi. The payment was made by Sanofi under a licensing a2014/1/20
-
FDA accepts Iroko's Zorvolex sNDA for reviewThe US Food and Drug Administration (FDA) is to review Iroko Pharmaceuticals' supplemental new drug application (sNDA) for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug (NSAI2014/1/17
-
Roche Reports New Method for Efficiently Transporting Antibodies Across the Blood-Brain BarrierResults published in Neuron demonstrate efficacy in preclinical mouse models of Alzheimer's disease. The scientific journal Neuron has published results on the Roche-designed Brain Shuttle technolo2014/1/17
-
FDA approves AstraZeneca and BMS' diabetes drug FARXIGAThe US Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squibb's (BMS) FARXIGA (dapagliflozin), a once-daily oral treatment for the improvement of glycaemic control in adu2014/1/16
-
Chelsea obtains FDA panel recommendation for Northera for treatment of symptomatic nOHThe Food and Drug Administration's (FDA) cardiovascular and renal drugs advisory committee (CRDAC) voted 16-1 to recommend approval for Chelsea Therapeutics' Northera (droxidopa) to treat symptomatic2014/1/16